CureVac puts lead oncology candidate on back burner and will only move it forward in combination therapies

17 Nov 2022
endpts.com
VaccineClinical ResultPhase 1mRNAImmunotherapy
CureVac is putting its lead cancer therapy on ice — for now. The trans-atlantic pharma with offices in Boston, MA and Germany put word of the new development in its Q3 earnings report Wednesday. CV8102 is a non-coding RNA therapy that has been tested both as a monotherapy and in combination with anti-PD-1 antibodies in early clinical trials. While preliminary results in solid tumors were reported at ESMO last year, CureVac reported new results just last week. Those new results showed that 17% of participants in the combination cohort experienced a partial response, with no objective responses seen in the 10 patients enrolled in the single-agent cohort. Five of those 10 in the single-agent cohort were previously treated with anti-CTLA-4 antibodies. CureVac added in its earnings report that final results are expected to be submitted for publication in the first half of next year. The biotech’s interim chief development officer Ulrike Gnad-Vogt noted in a statement last week that the data CureVac collected so far confirm the candidate’s safety and immuno-modulatory profile, but added that “Given our strategic focus on developing a meaningful portfolio of mRNA-based therapeutic cancer vaccines, we will seek to assess CV8102’s potential as a complementary technology.” A CureVac spokesperson added to Endpoints News that “We consider the clinically demonstrated immunomodulatory characteristics of CV8102 a highly valuable technology. Our goal is to ensure that further clinical development of CV8102 is in alignment with our strategic focus on the development of mRNA-based cancer vaccine candidates that target tumor-specific antigens.” The spokesperson also said that the company “will assess the potential for CV8102 to be integrated into our mRNA cancer vaccine priority program.” In the meantime, CureVac said it plans to share data from four different Phase I trials — two in flu and two in Covid-19 — in Q1 2023.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.